Tonix Pharmaceuticals Holding Corp. (TNXP) News
Filter TNXP News Items
TNXP News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TNXP News Highlights
- TNXP's 30 day story count now stands at 5.
- Over the past 9 days, the trend for TNXP's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- DEC, DRUG and PR are the most mentioned tickers in articles about TNXP.
Latest TNXP News From Around the Web
Below are the latest news stories about TONIX PHARMACEUTICALS HOLDING CORP that investors may wish to consider to help them evaluate TNXP as an investment opportunity.
Tonix Pharmaceuticals Announces Registered Direct Offering of up to $144 MillionLed by healthcare-focused institutional investors. $30 million financing upfront with up to an additional $114 million tied to the exercise of warrants. CHATHAM, N.J., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the Company has signed securities purchase agreements with certain healthcare-focused institutional investors that have agreed to pr |
Tonix Pharmaceuticals Announces Highly Statistically Significant and Clinically Meaningful Topline Results in Second Positive Phase 3 Clinical Trial of TNX-102 SL for the Management of FibromyalgiaFigure 1 Pain Reduction Over Course of Study Phase 3 RESILIENT study of TNX-102 SL successfully demonstrated daily pain reduction over placebo (primary endpoint, p = 0.00005) All six key secondary endpoints, including patient global impression, fibromyalgia-specific symptoms and dysfunction, fatigue and sleep measures were significantly improved (all p ≤ 0.001) Positive results support planned New Drug Application (NDA) submission to the FDA in the second half of 2024An estimated 6 million to 1 |
Hope On The Horizon: Tonix Pharmaceuticals (NASDAQ:TNXP) Could Be On the Cusp of Changing Fibromyalgia Treatment Options With TNX-102 SLTopline Data from a Registration-Enabling Phase 3 Clinical Trial is Due Later This Month.CHATHAM, NJ / ACCESSWIRE / December 14, 2023 / Fibromyalgia is a chronic disorder characterized by widespread pain, fatigue, sleep problems and brain fog. It ... |
Tonix Pharmaceuticals shared details of IND clearance for Phase 2 trial of TNX-2900Tonix Pharmaceuticals CEO Dr Seth Lederman joined Steve Darling from Proactive to delve into the significant development involving the US Food and Drug Administration (FDA)'s clearance of the Inves... |
Tonix Pharmaceuticals to Present at The National Academies Committee on the Current State of Research, Development, and Stockpiling of Smallpox Medical Countermeasures Public MeetingCHATHAM, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Seth Lederman M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at the National Academies of Sciences, Engineering, and Medicine Committee on the Current State of Research, Development, and Stockpiling of Smallpox Medical Countermeasures public meeting on Thursday, |
TNXP: Topline Results from Phase 3 RESILIENT Study in Fibromyalgia Expected in Late December 2023…By David Bautz, PhD NASDAQ:TNXP READ THE FULL TNXP RESEARCH REPORT Business Update Topline Results for Phase 3 RESILIENT Study Expected Late December 2023 On November 15, 2023, Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) announced the completion of the clinical phase of the Phase 3 RESILIENT trial of TNX-102 SL 5.6 mg for the management of fibromyalgia. The double blind, placebo controlled |
Tonix Pharmaceuticals Announces IND Clearance by the FDA for Phase 2 Trial of TNX-2900 for the Treatment of Prader-Willi Syndrome, the Most Common Genetic Cause of Life-Threatening Childhood ObesityTNX-2900 is a proprietary magnesium-potentiated formulation of intranasal oxytocin, a naturally occurring hormone that reduces appetite and eating Preclinical data show magnesium-potentiation increases the potency of exogenous oxytocin Formulations of intranasal oxytocin without magnesium have reported inconsistent results in clinical trials of Prader Willi Syndrome1,2 CHATHAM, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company |
Tonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in DecemberCHATHAM, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Tonix Management will present and host investor meetings at the following December investor conferences: NobleCon 19, Noble Capital Markets’ 19th Annual Emerging Growth Equity Conference Presenter:Jessica Morris, Chief Operating Officer of Tonix PharmaceuticalsDate:Monday, December 4, |
Tonix Pharmaceuticals' CEO reveals next-generation COVID vaccine technology chosen for key programTonix Pharmaceuticals CEO Dr Seth Lederman recently joined Steve Darling from Proactive to share exciting news about their COVID vaccine, TNX-1800, selected for testing in Project Next Gen, a White... |
Tonix Pharmaceuticals finish Phase 3 trial of TNX-102 SL for management of FibromyalgiaTonix Pharmaceuticals CEO Dr Seth Lederman recently joined Steve Darling from Proactive to shed light on the latest developments in their research efforts. The company has successfully concluded th... |